Emergent BioSolutions (EBS) Tops Q1 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Emergent BioSolutions (EBS) Tops Q1 EPS by 6c

Emergent BioSolutions Reports Financial Results For First Quarter 2022

April 28, 2022 4:06 PM EDT

Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36MTemporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements

GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2022.

Emergent remains focused on our strategic plan to grow within public health threat markets where we can positively impact patients and customers, said Robert G. Kramer, president and CEO of Emergent BioSolutions. Our diversified business model, disciplined operating... More